Residual psychomotor effects following reversal of midazolam sedation with flumazenil.
The ability of flumazenil to reverse the effects of midazolam sedation was examined in a randomised, crossover, placebo controlled study in six male volunteers. Subjects received intravenous injections of either (a) midazolam 10 mg followed 10 minutes later by flumazenil 1.0 mg or (b) midazolam 10 mg followed after 10 minutes by flumazenil 4 mg or (c) placebo followed after 10 minutes by placebo. Post reversal drug effects were examined using a psychomotor battery (critical flicker fusion, digit symbol substitution, tapping test, ball-bearing test, number recall, reflex time) and linear analogue mood scales. It was found that a residual psychomotor deficit was present following flumazenil and that this persisted for up to 125 minutes after the 1.0 mg dose and 65 minutes following 4 mg. A small deterioration in performance was apparent after initial reversal with 1.0 mg, the peak deterioration occurring at 35 minutes.
Short
T G
TG
Department of Anaesthesia, Wellington School of Medicine, New Zealand.
Galletly
D C
DC
D000328:Adult; D000339:Affect / Q000187:drug effects; D004244:Dizziness / Q000139:chemically induced; D005442:Flumazenil / Q000009:adverse effects / Q000627:therapeutic use*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use*; D008124:Locomotion / Q000187:drug effects; D008297:Male; D011939:Mental Recall / Q000187:drug effects; D008874:Midazolam / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D009483:Neuropsychological Tests; D011597:Psychomotor Performance / Q000187:drug effects*
D006993:Hypnotics and Sedatives; D005442:Flumazenil; D008874:Midazolam